TransMedics (TMDX) Net Margin (2018 - 2026)

TransMedics' Net Margin history runs 9 years deep, the most recent figure standing at 4.21% for Q1 2026.

• On a quarterly basis, Net Margin fell 1368.0% year-over-year to 4.21% in Q1 2026; TTM through Mar 2026 was 30.11%, a 2731.0% increase from a year earlier, with the FY2025 full-year figure at 31.43%, up 3140.0% from the prior year.
• Net Margin fell to 4.21% in Q1 2026 per TMDX's latest filing, from 77.71% in the prior quarter.
• Across five years, Net Margin topped out at 77.71% in Q4 2025 and bottomed at 66.51% in Q1 2022.
• The 5-year median for Net Margin is 2.46% (2023), against an average of 4.38%.
• Across the five-year window, Net Margin soared 21246 bps in 2022 and slumped 2585 bps in 2024, its largest moves.
• Year by year, Net Margin stood at 21.42% in 2022, then soared by 111 bps to 2.46% in 2023, then sank by 1051 bps to 23.39% in 2024, then surged by 432 bps to 77.71% in 2025, then plunged by 95 bps to 4.21% in 2026.
• Per Business Quant, the three latest TMDX Net Margin figures stand at 4.21% (Q1 2026), 77.71% (Q4 2025), and 16.91% (Q3 2025).